schema_version: "2.0"

metadata:
  version: "1.0.0"
  created: "2025-12-06"
  curator: "Preclinical Drug Development Team"
  description: "Canonical frameworks for preclinical/translational oncology drug development"

# ============================================================================
# TIER 1: ESSENTIAL PRIORS (Always loaded)
# ============================================================================

tier_1_essential:
  frameworks:

    ich_m3r2:
      citation:
        authors: "ICH Expert Working Group"
        title: "Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2)"
        year: 2009
        access: "open"

      domain: "regulatory_guidance"
      strength: "CRITICAL"
      applies_to: ["all_scenarios"]

      summary: |
        ICH M3(R2) provides guidance on timing of nonclinical studies relative to
        clinical development. Key principles include:
        - Duration of toxicology studies based on intended clinical duration
        - Safety pharmacology core battery requirements
        - Reproductive toxicology timing relative to patient population
        - Carcinogenicity study requirements

      key_recommendations:
        - "2-week toxicity studies support Phase I single-dose and short-term dosing"
        - "1-month toxicity studies support Phase II dosing up to 1 month"
        - "Safety pharmacology core battery before first human exposure"
        - "Genotoxicity testing before Phase I (unless life-threatening indication)"

    ich_s9:
      citation:
        authors: "ICH Expert Working Group"
        title: "Nonclinical Evaluation for Anticancer Pharmaceuticals S9"
        year: 2009
        access: "open"

      domain: "oncology_regulatory"
      strength: "CRITICAL"
      applies_to: ["all_scenarios"]

      summary: |
        ICH S9 provides specific guidance for anticancer drug development:
        - Reduced nonclinical requirements for advanced cancer indications
        - Flexibility in genotoxicity and reproductive toxicology timing
        - Focus on safety margins rather than NOAEL-based dose selection
        - Guidance on combination studies

      key_recommendations:
        - "Rodent-only toxicity acceptable for advanced cancer FIH"
        - "Genotoxicity studies not required before Phase I in advanced cancer"
        - "Embryo-fetal development studies may be deferred to post-approval"
        - "10% HNSTD or 1/6 highest non-severely toxic dose for FIH starting dose"

    fda_ind_guidance:
      citation:
        authors: "FDA"
        title: "Content and Format of Investigational New Drug Applications (INDs)"
        year: 2023
        access: "open"

      domain: "regulatory_guidance"
      strength: "CRITICAL"
      applies_to: ["all_scenarios"]

      summary: |
        FDA IND guidance outlines requirements for initiating clinical trials:
        - CMC information for drug substance and product
        - Pharmacology and toxicology data requirements
        - Clinical protocol and investigator information
        - Safety reporting requirements

      key_recommendations:
        - "IND submission at least 30 days before planned trial start"
        - "GLP compliance for pivotal toxicology studies"
        - "Stability data supporting proposed clinical use period"
        - "Adequate characterization of drug substance identity and purity"

    target_product_profile:
      citation:
        authors: "FDA"
        title: "Target Product Profile - A Strategic Development Process Tool"
        year: 2007
        access: "open"

      domain: "development_strategy"
      strength: "HIGH"
      applies_to: ["all_scenarios"]

      summary: |
        TPP framework for defining target attributes of a drug product:
        - Indication and intended use
        - Target efficacy endpoints and minimally acceptable improvement
        - Target safety profile relative to existing therapies
        - Proposed dosing regimen and route of administration

      key_recommendations:
        - "Define TPP early and update throughout development"
        - "TPP should differentiate from standard of care"
        - "Include both minimal and optimal target profiles"
        - "Use TPP to guide go/no-go decisions"

# ============================================================================
# TIER 2: SCENARIO-SPECIFIC PRIORS
# ============================================================================

tier_2_scenario_specific:

  target_validation:
    - id: genetic_dependency_framework
      citation:
        authors: "Tsherniak A, et al"
        title: "Defining a Cancer Dependency Map"
        journal: "Cell"
        year: 2017
        pmid: "28753430"

      domain: "target_validation"
      strength: "HIGH"

      summary: |
        Project Achilles framework for identifying cancer dependencies using
        genome-wide CRISPR screens. Key concepts:
        - Essential vs context-specific dependencies
        - Biomarker-dependency correlations
        - Priority scoring for therapeutic targets

      key_recommendations:
        - "Validate target dependency in relevant cell line panels"
        - "Correlate dependency with biomarker status"
        - "Distinguish essential vs cancer-specific dependencies"
        - "Consider genetic vs pharmacologic target validation"

  pk_pd:
    - id: human_dose_prediction
      citation:
        authors: "Mahmood I"
        title: "Application of Allometric Principles for the Prediction of Pharmacokinetics in Human and Veterinary Drug Development"
        journal: "Advanced Drug Delivery Reviews"
        year: 2007
        pmid: "17673321"

      domain: "pk_prediction"
      strength: "HIGH"

      summary: |
        Allometric scaling principles for human PK prediction:
        - Simple allometry using body weight
        - Correction factors for hepatically cleared compounds
        - Species selection considerations
        - Limitations and when to use PBPK instead

      key_recommendations:
        - "Use multiple species for robust prediction"
        - "Apply correction factors for high clearance compounds"
        - "Consider PBPK for complex PK or specific populations"
        - "Validate predictions with human PK data when available"

    - id: therapeutic_index_framework
      citation:
        authors: "Muller PY, Milton MN"
        title: "The determination and interpretation of the therapeutic index in drug development"
        journal: "Nature Reviews Drug Discovery"
        year: 2012
        pmid: "22653210"

      domain: "safety_assessment"
      strength: "HIGH"

      summary: |
        Framework for assessing therapeutic index:
        - Exposure-based safety margins
        - AUC and Cmax comparisons to NOAEL
        - Target coverage considerations
        - Therapeutic window estimation

      key_recommendations:
        - "Calculate exposure multiples at projected efficacious dose"
        - "Consider free drug concentrations for safety margins"
        - "Integrate target coverage with safety assessments"
        - "Document therapeutic index evolution through development"

  biomarker:
    - id: fda_biomarker_qualification
      citation:
        authors: "FDA"
        title: "Biomarker Qualification: Evidentiary Framework"
        year: 2018
        access: "open"

      domain: "biomarker_development"
      strength: "HIGH"

      summary: |
        FDA framework for biomarker qualification:
        - Context of Use (COU) definition
        - Evidentiary standards for different COUs
        - Benefit-risk considerations for biomarker use
        - Regulatory pathways for qualification

      key_recommendations:
        - "Clearly define Context of Use for biomarker"
        - "Analytical validation before clinical validation"
        - "Prospective-retrospective design acceptable for some COUs"
        - "Consider fit-for-purpose validation"

  competitive_intel:
    - id: competitive_landscape_framework
      citation:
        authors: "Drug Development Best Practices"
        title: "Competitive Intelligence Framework for Oncology Drug Development"
        year: 2024

      domain: "competitive_strategy"
      strength: "MODERATE"

      summary: |
        Framework for competitive landscape analysis:
        - Mechanism of action differentiation
        - Clinical development timelines and milestones
        - Efficacy and safety profile comparisons
        - Market positioning considerations

      key_recommendations:
        - "Monitor clinical trial registrations and publications"
        - "Identify differentiation opportunities vs competitors"
        - "Assess combination potential"
        - "Consider regulatory pathway implications"

# ============================================================================
# TIER 3: SUPPLEMENTAL CONTEXT
# ============================================================================

tier_3_supplemental:
  frameworks:

    pbpk_best_practices:
      citation:
        authors: "Jones H, et al"
        title: "Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development"
        journal: "CPT Pharmacometrics Syst Pharmacol"
        year: 2015
        pmid: "26312937"

      domain: "pk_modeling"
      strength: "MODERATE"

      summary: |
        Best practices for PBPK modeling in drug development:
        - Model verification and validation
        - Sensitivity analysis requirements
        - Application to DDI prediction
        - Regulatory acceptance considerations

      key_recommendations:
        - "Verify system parameters against known compounds"
        - "Perform local and global sensitivity analyses"
        - "Document model assumptions and limitations"
        - "Use PBPK for mechanistic DDI predictions"

# ============================================================================
# PERSONA-FRAMEWORK MAPPING
# ============================================================================

persona_framework_defaults:

  Bioscience Lead:
    tier_1_frameworks:
      - target_product_profile
    tier_2_scenarios:
      - target_validation

  Translational Medicine Scientist:
    tier_1_frameworks:
      - ich_s9
      - target_product_profile
    tier_2_scenarios:
      - biomarker
      - target_validation

  Competitive Intelligence Analyst:
    tier_1_frameworks:
      - target_product_profile
    tier_2_scenarios:
      - competitive_intel

  DMPK Scientist:
    tier_1_frameworks:
      - ich_m3r2
    tier_2_scenarios:
      - pk_pd

  Clinical Pharmacologist:
    tier_1_frameworks:
      - ich_m3r2
      - ich_s9
    tier_2_scenarios:
      - pk_pd

  Toxicology Expert:
    tier_1_frameworks:
      - ich_m3r2
      - ich_s9
      - fda_ind_guidance
    tier_2_scenarios: []

  Biomarker Strategist:
    tier_1_frameworks:
      - target_product_profile
    tier_2_scenarios:
      - biomarker

  Regulatory Science Expert:
    tier_1_frameworks:
      - ich_m3r2
      - ich_s9
      - fda_ind_guidance
    tier_2_scenarios: []

  Panel Chair:
    tier_1_frameworks:
      - target_product_profile
      - ich_s9
    tier_2_scenarios:
      - competitive_intel
